Skip to Content


Active Substance: votumumab
Common Name: votumumab
ATC Code: V09IX
Marketing Authorisation Holder: KS Biomedix Limited
Active Substance: votumumab
Status: Withdrawn
Authorisation Date: 1998-09-25
Therapeutic Area: Colorectal Neoplasms Ultrasonography Tomography, X-Ray Computed
Pharmacotherapeutic Group: Diagnostic radiopharmaceuticals

Therapeutic Indication

After reconstitution with sodium pertechnetate [99mTc] solution, HumaSPECT [99mTc] is indicated in patients with histologically proven carcinoma of the colon or rectum for imaging of recurrence and/or metastases. HumaSPECT [99mTc] is employed, in the above mentioned patients, as an adjunct to standard non invasive imaging techniques, such as ultrasonography or CT scan, in the following situations.
• Patients with evidence of recurrence and/or metastatic carcinoma of the colon or rectum, who are undergoing an evaluation for extent of disease, such as prior to surgical resection and/or other therapy.
• Patients with suspected recurrence and/or metastatic carcinoma of the colon or rectum in association with rising levels of carcinoembryonic antigen (CEA).

The marketing authorisation for HumaSPECT has not been renewed by the marketing authorisation holder and is now withdrawn.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.